• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Gains 1%; Macy's Plans To Close 150 Stores

    2/27/24 12:24:14 PM ET
    $HIMS
    $JANX
    $M
    $NERV
    Medical/Nursing Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HIMS alert in real time by email

    U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 150 points on Tuesday.

    The Dow traded down 0.39% to 38,915.65 while the NASDAQ rose 0.15% to 15,999.50. The S&P 500 also fell, dropping, 0.03% to 5,067.80.

    Check This Out: Wall Street's Most Accurate Analysts' Views On 3 Risk Off Stocks With Over 5% Dividend Yields

     

    Leading and Lagging Sectors

     

    Utilities shares rose by 1.5% on Tuesday.

    In trading on Tuesday, energy shares fell by 0.5%.

     

    Top Headline

     

    Macy’s Inc (NYSE:M) reported mixed quarterly results and announced plans to close 150 stores.

    The company reported fourth-quarter adjusted EPS of $2.45, beating the analyst consensus of $1.96. Quarterly revenue of $8.12 billion missed the analyst consensus of $8.15 billion. Sales fell 1.7% year over year.

    Macy’s announced a new strategy, “A Bold New Chapter,” designed to return the company to enterprise growth. The company plans to focus on Macy’s resources by closing approximately 150 underproductive locations through 2026.

     

    Equities Trading UP

     

    Janux Therapeutics, Inc. (NASDAQ:JANX) shares shot up 195% to $44.47 after the company announced updated clinical data for both of its clinical programs.

    Shares of Hims & Hers Health, Inc. (NYSE:HIMS) got a boost, surging 35% to $13.80 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.

    Viking Therapeutics, Inc. (NASDAQ:VKTX) shares were also up, gaining 100% to $76.92 after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints.

     

    Equities Trading DOWN

     

    Minerva Neurosciences, Inc. (NASDAQ:NERV) shares dropped 58% to $2.88 after the company announced it received a Complete Response Letter from the FDA for the New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.

    Shares of Thoughtworks Holding, Inc. (NASDAQ:TWKS) were down 28% to $3.33 after the company reported worse-than-expected fourth-quarter financial results and issued weak guidance.

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) was down, falling 32% to $0.2901 after the company announced pricing of $1.5 million underwritten public offering of common stock at a price of $0.30/share together with investor commitment for additional $1 million.

    Also Check This Out: Top 3 Energy Stocks That Could Sink Your Portfolio In Q1

     

    Commodities

     

    In commodity news, oil traded up 1% to $78.35 while gold traded up 0.2% at $2,042.60.

    Silver traded fell 0.2% to $22.485 on Tuesday while copper rose 0.5% to $3.8520.

     

    Euro zone

     

    European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.24%, London’s FTSE 100 rose 0.04% while Spain’s IBEX 35 Index fell 0.22% The German DAX gained 0.78% French CAC 40 rose 0.29% while Italy’s FTSE MIB Index rose 0.48%.

    Bank lending to households in the Eurozone rose by 0.3% year-over-year to EUR 6.870 trillion for January. The consumer confidence indicator in France declined to 89 in February versus around two-year high level of 91 in the prior month. The GfK Consumer Climate Indicator for Germany climbed to a reading of -29.0 heading into March compared to February's level of 29.6.

     

    Asia Pacific Markets

     

    Asian markets closed higher on Tuesday, with Japan’s Nikkei 225 gaining 0.01%, Hong Kong’s Hang Seng Index climbing 0.94%, China’s Shanghai Composite Index surging 1.29% and India’s S&P BSE Sensex gaining 0.4%.

    Hong Kong recorded a trade surplus of $3.6 billion in January compared to a year-ago deficit of $25.4 billion. The annual inflation rate in Japan slowed to 2.2% in January compared to 2.6% in the earlier month.

     

    Economics

     

    U.S. durable goods orders fell by 6.1% month-over-month in January compared to a 0.3% decline in December.

    The FHFA house price index rose 0.1% in December following a 0.4% increase in November.

    The S&P CoreLogic Case-Shiller 20-city home price index climbed by 6.1% year-over-year in December.

    The Dallas Fed general business activity index for Texas’ service sector rose to -3.9 in February from -9.3 in the previous month.

    Now Read This: Roku, Crocs And 2 Other Stocks Insiders Are Selling

     

    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS
    $JANX
    $M
    $NERV

    CompanyDatePrice TargetRatingAnalyst
    Hims & Hers Health Inc.
    $HIMS
    2/24/2026Buy → Neutral
    BTIG Research
    Macy's Inc
    $M
    1/14/2026$27.00Buy
    Jefferies
    Hims & Hers Health Inc.
    $HIMS
    1/12/2026$33.00In-line
    Evercore ISI
    Macy's Inc
    $M
    12/10/2025Neutral
    Guggenheim
    Hims & Hers Health Inc.
    $HIMS
    12/9/2025$48.00Overweight
    Barclays
    Macy's Inc
    $M
    12/4/2025$22.00 → $25.00Market Perform
    Telsey Advisory Group
    Macy's Inc
    $M
    11/28/2025$17.00 → $22.00Market Perform
    Telsey Advisory Group
    Janux Therapeutics Inc.
    $JANX
    11/18/2025Peer Perform
    Wolfe Research
    More analyst ratings

    $HIMS
    $JANX
    $M
    $NERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Casper Joseph Michael

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    2/17/26 7:00:43 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Casper Joseph Michael

    3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    2/17/26 7:00:15 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Go William was granted 44,000 shares (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    2/4/26 8:01:40 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $JANX
    $M
    $NERV
    SEC Filings

    View All

    SEC Form DEFA14A filed by NRX Pharmaceuticals Inc.

    DEFA14A - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    2/24/26 5:00:18 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Hims & Hers Health Inc.

    S-8 - Hims & Hers Health, Inc. (0001773751) (Filer)

    2/24/26 4:34:53 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 10-K filed by Hims & Hers Health Inc.

    10-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    2/23/26 5:20:28 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    $JANX
    $M
    $NERV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

    4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)

    4/8/25 7:05:30 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

    4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

    4/2/25 6:29:36 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

    4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

    3/7/25 6:05:32 PM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $JANX
    $M
    $NERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hims & Hers Health downgraded by BTIG Research

    BTIG Research downgraded Hims & Hers Health from Buy to Neutral

    2/24/26 7:59:48 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Jefferies resumed coverage on Macy's with a new price target

    Jefferies resumed coverage of Macy's with a rating of Buy and set a new price target of $27.00

    1/14/26 8:43:49 AM ET
    $M
    Department/Specialty Retail Stores
    Consumer Discretionary

    Evercore ISI initiated coverage on Hims & Hers Health with a new price target

    Evercore ISI initiated coverage of Hims & Hers Health with a rating of In-line and set a new price target of $33.00

    1/12/26 8:13:43 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    $JANX
    $M
    $NERV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

    NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER)Oral guidance received at the meeting provides a path to filing an application for New Drug Approval of NRX-100 under already-awarded Fast Track Designation based on existing clinical trial data and Real World EvidenceBased on the guidance, NRx will seek a broader proposed indication for NRX-100 to serve patients with treatment-resistant depression who may have suicidality rather than only the subset with suicidality WILMINGTON, Del., Feb. 17, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, I

    2/17/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $JANX
    $M
    $NERV
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

    Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January 26, 2026. Dr. Go succeeds Zachariah McIver, D.O., Ph.D., who will be leaving the Company to pursue other opportunities. Dr. Go brings more than 20 years of hematology and oncology experience, leading programs from early clinical development through pivotal trials, global regulatory approvals, and first-i

    1/26/26 7:00:00 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

    Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.

    1/7/26 7:00:00 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $JANX
    $M
    $NERV
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

    Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full EnrollmentVK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 MillionSAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended

    2/11/26 4:16:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

    Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time  SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.

    2/4/26 4:05:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HIMS
    $JANX
    $M
    $NERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Thoughtworks Holding Inc.

    SC 13D/A - Thoughtworks Holding, Inc. (0001866550) (Subject)

    11/15/24 4:15:12 PM ET
    $TWKS
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by Thoughtworks Holding Inc.

    SC 13D/A - Thoughtworks Holding, Inc. (0001866550) (Subject)

    11/15/24 4:05:56 PM ET
    $TWKS
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care